Clinical Trial Successfully Repurposes Cancer Drug for Hereditary Bleeding Disorder
September 19, 2024
September 19, 2024
BOSTON, Massachusetts, Sept. 19 (TNSres) -- Mass General Brigham issued the following news release:
* * *
A clinical trial, involving researchers and patients at Mass General Hospital, found that an oral drug approved for treating a blood cancer was effective at reducing the severity of nosebleeds associated with HHT
Key Takeaways
Hereditary hemorrhagic telangiectasia is a bleeding disorder for which there are currently no approved treatments.< . . .
* * *
A clinical trial, involving researchers and patients at Mass General Hospital, found that an oral drug approved for treating a blood cancer was effective at reducing the severity of nosebleeds associated with HHT
Key Takeaways
Hereditary hemorrhagic telangiectasia is a bleeding disorder for which there are currently no approved treatments.< . . .